stockportfolio.pro
Stocks / HAE vs NAMS
HAE vs NAMS
Haemonetics Corporation and NewAmsterdam Pharma Company N.V. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Haemonetics Corporation (HAE) | NewAmsterdam Pharma Company N.V. (NAMS) | |
|---|---|---|
| Market cap | $3.6B | $3.5B |
| Revenue (latest FY) | $1.33B | $22.50M |
| Net income (latest FY) | $97.31M | $-203.82M |
| Revenue growth (5y CAGR) | 8.9% | — |
| Net margin | 7.3% | -905.7% |
| Return on equity | 12.2% | -29.8% |
| P/E ratio | 38.4 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 9 | 0 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open HAE — free Open NAMS — freeFrequently asked questions
Which is bigger, HAE or NAMS?
Haemonetics Corporation is larger by market capitalization — $3.6B versus $3.5B.
Which grows faster, HAE or NAMS?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.